A revolutionary regenerative therapy for management of chronic inflammatory diseases based on neonatal Mesenchymal Stem Cells

Informazioni relative al progetto

NeoCellBank

ID dell’accordo di sovvenzione: 864301

DOI

10.3030/864301

Progetto chiuso

Data della firma CE 29 Aprile 2019

Data di avvio 1 Maggio 2019

Data di completamento 31 Agosto 2019

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

VETBIOBANK SAS
France

Periodic Reporting for period 1 - NeoCellBank (A revolutionary regenerative therapy for management of chronic inflammatory diseases based on neonatal Mesenchymal Stem Cells)

Periodo di rendicontazione: 2019-05-01 al 2019-08-31

Sintesi del contesto e degli obiettivi generali del progetto

At Vetbiobank we verified the feasibility of NeoCellBank project to optimize our disruptive cell therapy biomanufacturing platform and release it into market. While we already demonstrated in a Proof of Concept study, long term safety and efficacy of our top-tier candidate, Canipren®-Joint to treat canine osteoarthritis, we plan to improve our manufacturing capability and technology transfer, prior to clinical validation. We assessed all the investment required to complete the project, for which we will pursue financing support of circa €2.5M from the EC scheme of Accelerator project. We have evaluated the potential of NeoCellBank to generate >€13M profit and new employment (+15 new job positions). We have already received proofs of interest from our key stakeholders: 3 public research centers, vet clinical investigators located in France and private pharma and biotech companies; we have already established a partnership to secure our European distribution channels with one top 10 vet pharma company. We concluded to continue with NeoCellBank project, motivated by the confirmation of the uniqueness and competitiveness of our innovation with this feasibility study.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

TECHNICAL FEASIBILITY, including: technology definition and transfer; Canipren®-Joint specification; analysis of validation procedures; detailed technical plan to increase TRL to 8; analysis of risks and design of a mitigation and contingency plan.
COMMERCIAL FEASIBILITY, including: market analysis; end-user´s segmentation; main competitors; definition of commercial strategy; SoA and FtO analysis; business model; commercialization and dissemination plan, including IPR strategy.
FINANCIAL FEASIBILITY, including: in-depth cost analysis to evaluate our capacity to take the innovation; business projections for the first five years after NeoCellBank market launch in a conservative sales scenario.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

NeoCellBank will be the first biomanufacturing platform able to yield neonatal MSC-based therapies from placental tissues for vet and human medicinal applications, improving the benefits (higher standardized treatment, higher cell proliferation capacity, and lower immunogenicity, among others) and avoiding ethical constrains usually associated to adult cells, and accelerating cell therapy development process in terms of cost, regulations and time-to-market. It will allow us to grow reaching >€36M revenue and +15 new employees after the 5th year of commercialization.

image.png